Alan E Thong1, Hongjuan Zhao1, Alexandre Ingels2, Maija P Valta3, Rosalie Nolley1, Jennifer Santos1, Sarah R Young1, Donna M Peehl4. 1. Department of Urology, Stanford University School of Medicine, Stanford, CA. 2. Department of Urology, Stanford University School of Medicine, Stanford, CA; Department of Urology, Centre Hospitalier Universitaire du Kremlin-Bicêtre, Kremlin-Bicêtre, France. 3. Department of Urology, Stanford University School of Medicine, Stanford, CA; Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland. 4. Department of Urology, Stanford University School of Medicine, Stanford, CA. Electronic address: dpeehl@stanford.edu.
Abstract
OBJECTIVE: Discovery of curative therapies for renal cell carcinoma (RCC) is hampered by lack of authentic preclinical models. Tumorgrafts, generated by direct implantation of patient-derived tissues into mice, have demonstrated superior ability to predict therapeutic response. We evaluated "tissue slice grafts" (TSGs) as an improved tumorgraft model of RCC. MATERIALS AND METHODS: Cores of fresh RCC were precision-cut at 300 µm and implanted under the renal capsule of RAG2(-/-)γC(-/-) mice. Engraftment rate, histology, biomarker expression, genetic fidelity, and metastatic potential were evaluated. Magnetic resonance imaging (MRI) was tested as a noninvasive method to measure tumor volume, and response to a targeted therapy was determined. RESULTS: All 13 cases of RCC engrafted and displayed characteristic histology and biomarkers. TSG volume quantified noninvasively by MRI highly correlated with graft weights, providing a unique tool for monitoring orthotopic growth. Moreover, in 2 cases, cancer cells from TSGs metastasized to clinically relevant sites, including bone. Microarray analysis and DNA sequencing demonstrated a high degree of correlation of global gene expression and von Hippel-Lindau (VHL) status between TSGs and parental tumors. Treatment of TSGs with sunitinib significantly decreased graft weight and mean vessel density compared with controls. CONCLUSION: The TSG model of RCC faithfully recapitulates tumor pathology, gene expression, genetic mutation, and drug response. The high engraftment rate and metastatic potential of this authentic model, in conjunction with the ability to generate large first-generation animal cohorts and to quantitate tumor volume at the orthotopic site by MRI, proffer significant advantages compared with other preclinical platforms.
OBJECTIVE: Discovery of curative therapies for renal cell carcinoma (RCC) is hampered by lack of authentic preclinical models. Tumorgrafts, generated by direct implantation of patient-derived tissues into mice, have demonstrated superior ability to predict therapeutic response. We evaluated "tissue slice grafts" (TSGs) as an improved tumorgraft model of RCC. MATERIALS AND METHODS: Cores of fresh RCC were precision-cut at 300 µm and implanted under the renal capsule of RAG2(-/-)γC(-/-) mice. Engraftment rate, histology, biomarker expression, genetic fidelity, and metastatic potential were evaluated. Magnetic resonance imaging (MRI) was tested as a noninvasive method to measure tumor volume, and response to a targeted therapy was determined. RESULTS: All 13 cases of RCC engrafted and displayed characteristic histology and biomarkers. TSG volume quantified noninvasively by MRI highly correlated with graft weights, providing a unique tool for monitoring orthotopic growth. Moreover, in 2 cases, cancer cells from TSGs metastasized to clinically relevant sites, including bone. Microarray analysis and DNA sequencing demonstrated a high degree of correlation of global gene expression and von Hippel-Lindau (VHL) status between TSGs and parental tumors. Treatment of TSGs with sunitinib significantly decreased graft weight and mean vessel density compared with controls. CONCLUSION: The TSG model of RCC faithfully recapitulates tumor pathology, gene expression, genetic mutation, and drug response. The high engraftment rate and metastatic potential of this authentic model, in conjunction with the ability to generate large first-generation animal cohorts and to quantitate tumor volume at the orthotopic site by MRI, proffer significant advantages compared with other preclinical platforms.
Authors: Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm Journal: Nat Med Date: 2011-10-23 Impact factor: 53.440
Authors: Hikmat A Al-Ahmadie; Darym Alden; Samson W Fine; Anuradha Gopalan; Karim A Touijer; Paul Russo; Victor E Reuter; Satish K Tickoo Journal: Am J Surg Pathol Date: 2011-07 Impact factor: 6.394
Authors: Manuel Hidalgo; Elizabeth Bruckheimer; N V Rajeshkumar; Ignacio Garrido-Laguna; Elizabeth De Oliveira; Belen Rubio-Viqueira; Steven Strawn; Michael J Wick; James Martell; David Sidransky Journal: Mol Cancer Ther Date: 2011-06-14 Impact factor: 6.261
Authors: Sumanta Kumar Pal; Stephen Williams; David Y Josephson; Courtney Carmichael; Nicholas J Vogelzang; David I Quinn Journal: Mol Cancer Ther Date: 2012-02-17 Impact factor: 6.261
Authors: Rozemarijn S van Rijn; Elles R Simonetti; Anton Hagenbeek; Marieke C H Hogenes; Roel A de Weger; Marijke R Canninga-van Dijk; Kees Weijer; Hergen Spits; Gert Storm; Louis van Bloois; Ger Rijkers; Anton C M Martens; Saskia B Ebeling Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Yiyu Dong; Brandon J Manley; Maria F Becerra; Almedina Redzematovic; Jozefina Casuscelli; Daniel M Tennenbaum; Ed Reznik; Song Han; Nicole Benfante; Ying-Bei Chen; Maria E Arcila; Omer Aras; Martin H Voss; Darren R Feldman; Robert J Motzer; Nicola Fabbri; John H Healey; Patrick J Boland; Mohit Chawla; Jeremy C Durack; Chung-Han Lee; Jonathan A Coleman; Paul Russo; A Ari Hakimi; Emily H Cheng; James J Hsieh Journal: Eur Urol Focus Date: 2016-08-25
Authors: Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl Journal: Clin Exp Metastasis Date: 2014-04-09 Impact factor: 5.150
Authors: Renuka Sriram; Mark Van Criekinge; Ailin Hansen; Zhen J Wang; Daniel B Vigneron; David M Wilson; Kayvan R Keshari; John Kurhanewicz Journal: NMR Biomed Date: 2015-07-23 Impact factor: 4.044
Authors: David Roife; Bingbing Dai; Ya'an Kang; Mayrim V Rios Perez; Michael Pratt; Xinqun Li; Jason B Fleming Journal: Clin Cancer Res Date: 2016-06-03 Impact factor: 12.531
Authors: Yiren Xiao; Hongjuan Zhao; Lei Tian; Rosalie Nolley; Anh N Diep; Anne Ernst; Katherine C Fuh; Yu Rebecca Miao; Rie von Eyben; John T Leppert; James D Brooks; Donna M Peehl; Amato J Giaccia; Erinn B Rankin Journal: Cancer Res Date: 2019-10-04 Impact factor: 12.701
Authors: Alexandre Ingels; Hongjuan Zhao; Alan E Thong; Matthias Saar; Maija P Valta; Rosalie Nolley; Jennifer Santos; Donna M Peehl Journal: Int J Cancer Date: 2013-11-18 Impact factor: 7.316